About Us

Management team


Jean-Yves Bonnefoy, PhD – President & CEO, Co-founder & Chairman of the Board

Jean-Yves Bonnefoy is CEO of Anagenesis Biotechnologies since January 2014 and President since April 2015. He is President of Syndivia & Board member of Peptimimesis. He is a member of the scientific advisory board of iTeos Therapeutics, Oncodesign & Amal Therapeutics. He is also member of the investment committee of the alsacian TTO SATT Conectus and of the steering committee of Matwin. He was for two mandates, President of the Life Sciences Competitiveness Cluster, Alsace BioValley.

Jean-Yves has more than 30 years of experience in pharmaceutical industry directing research and development projects. Before joining Anagenesis, he held the position of VP, R&D of Transgene for 9 years. From 2002 to 2005, he launched and managed the Cancéropôle Lyon Rhône-Alpes. From 1992 to 2002, he headed the Centre d’immunologie Pierre Fabre. From 1998 to 2002, he was Director of the Immunology Department of the Glaxo-Wellcome Institute in Switzerland. From 1985 to 1987, he was scientist at the Research Centre of Schering-Plough in France.

Jean-Yves holds a PhD in Immunology, a “Thèse de 3ème cycle” in Biochemistry and followed the Senior Management Program of the London Business School, in the UK. He is author and co-author of more than 230 publications and reviews.


Cécile Jacques, PhD – Head of Operations

Cécile Jacques joined Anagenesis in April 2019 as Head of Operations. Cécile holds a PhD in Molecular and Cellular Biology from Strasbourg University (IGBMC Institute) and a Master in Intellectual Property Strategy and Innovation. After a post-doc at the Institute of Neurosciences of Alicante in Spain, she has gathered a nine-year experience in technology transfer first as Business Officer for 3 years followed by a position of Early Stage Portfolio Manager and Investment Analyst in the life science domain.


Aurore Hick, PhD – Lab Head

Aurore Hick joined Anagenesis in 2014 and is managing the R&D team. Aurore obtained her PhD in Molecular and Cellular Biology in 2014 from Strasbourg University, IGBMC Institute. Before that Aurore obtained an Engineer diploma in Biotechnology and Pharmacology from Polytech’Nice Sophia Engineering School in 2010.



Ilka Wicke

Ilka is an Investment Director in the Boehringer Ingelheim Corporate Venture Fund. Over the last years, she has been involved in several investments of the fund. She served as board member of Promethera Bioscience in Brussels and Pcovery in Copenhagen. She is currently on the Boards of Metabomed in TelAviv, Cadior Pharmaceuticals in Hannover and Anagenesis in Strasbourg. In addition, she is member of the Investment Committee of the High Tech Gründer Fund (HTGF) the largest publicly backed Seed Investment Fund in Germany based in Bonn.

Ilka has studied organic chemistry and obtained her PhD from the Johann Wolfgang Goethe University in Frankfurt. Following her graduation she spent a year in academic research as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy approaches. She joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery approaches. Thereafter, Ilka spent more than 13 years in the Corporate Licensing Division of Boehringer Ingelheim where she was responsible for the evaluation, negotiation and the management of several global licensing transactions. In 2009 Ilka participated in the creation of the Boehringer Ingelheim Venture Fund as a strategic component of Boehringer Ingelheim and has since then been an active Investment Manager in the Fund.

 Jean-François Rax

Jean-François Rax

Jean-François Rax joined Capital Grand Est in April 2014 as Investment Manager for Cap Innov’Est, a €45M seed fund, where he carried out 11 investments in life sciences. Prior to joining Capital Grand Est and since 2008, Jean-François was an Associate at Inserm Transfert Initiative, a €40M seed fund dedicated to life sciences and human health. In addition, he was also the Head of the company creation department at Inserm Transfert where he actively helped and coached many researchers and entrepreneurs to define their business model and to refine their strategy. Owing to his previous experiences, he has also a solid background in technology transfer, licensing and marketing strategy. Jean-François is a graduate in engineering from INSA (Lyon).










GKHeadShot (4)

Philippe Grand

Philippe Grand, currently an Associate at Ernst & Young, is the French representative of the E & Y Life Sciences network, and is also responsible for the young innovative start-ups market and for the EY Venture Capitalist Advisory Group to facilitate trade between major accounts of the pharmaceutical industry, innovative start-ups and European venture capital firms.

For 25 years, Philippe GRAND conducted more than 500 missions to support the creation of technology companies including the negotiation of alliances, technology transfers, fundraisings, validation of launch strategies, and financial and legal engineering related to the creation of activities in different sectors and in particular the health sector.

He has also worked with venture capital firms, Technology Transfer Offices, incubators, the Ministry of Research and Innovation and BPI France for the expert assessment of innovative projects.

Philippe GRAND is part of the international team that annually conducts Beyond Borders, the EY Global Biotechnology Report and is involved in the emergence of a national initiative around personalized medicine.

Gordon Keller, 

Prof. Gordon Keller is currently the Director of the McEwen Stem Cell Institute at the University Health Network in Toronto. He is a scientific co-founder of BlueRock Therapeutics and is best known for his research in lineage specific differentiation of mouse and human pluripotent stem cells. His lab was one of the first to successfully differentiate human pluripotent stem cells into the multiple cardiac lineages found in the human heart.

Prof. Gordon Keller received a PhD in Immunology from the University of Alberta in 1979. Following a post-doctoral fellowship at the Ontario Cancer Institute in Toronto, he moved to Europe and worked as a member of the Basel Institute for Immunology in Switzerland and then as a visiting professor at the Research Institute of Molecular Pathology in Austria. In 1990, Prof.  Keller relocated to the United States to  the National Jewish Centre for Immunology and Respiratory Medicine in Denver Colorado. In 1999 he moved to New York, to a position of Professor in the Department of Gene and Cell Medicine at the Mt. Sinai School of Medicine. In 2005, he was appointed as the inaugural Director of the Black Family Stem Cell Institute at Mt. Sinai.  In 2007, Prof.  Keller returned to Canada  as Director of the McEwen Stem Cell Institute.